Veterinary pharmaceutical company Norbrook Laboratories has filed court proceedings after a delegate of IP Australia tossed its opposition to a patent by Bayer New Zealand for a bovine antiseptic treatment.
Brisbane clothing company Lorna Jane has been fined almost $40,000 for implying that its ‘anti-virus activewear’ prevents against infectious diseases such as COVID-19.
A judge has ordered private health insurer Medibank to pay $5 million in penalties for rejecting the claims of hundreds of members who were entitled to coverage for critical medical procedures, including spinal surgery.
Global animal health company Zoetis has told the lead applicants in a class action over horse vaccines to “put up or shut up” and produce evidence disclosing an alleged scientific link between the hendra virus vaccine and certain alleged adverse side effects.
The lead applicants in a class action against The Cosmetic Institute have added 11 cosmetic surgeons to the lawsuit, alleging they conducted breast augmentation surgery in an “incompetent” manner.
Mylan Health has lost its challenge to a ruling that invalidated three patents related to its blockbuster cholesterol drug Lipidil, despite the appeals court finding the primary judge had erred by ruling that proof of intention was required for Swiss-style claims.
A judge has adjourned an interlocutory application because of deficient pleadings in a class action brought against three medical device manufacturers and a former doctor on behalf of thousands of women who claim to have suffered lifelong complications from pelvic mesh implants.
A delegate of IP Australia has tossed opposition by veterinary pharmaceutical company Norbrook Laboratories to a patent by rival animal health specialist Bayer New Zealand for a bovine antiseptic treatment.
The company that operates the Newmarch House nursing home in Sydney is facing a possible class action after a coronavirus outbreak at the facility resulted in the deaths of 19 residents.
Drug manufacturer Janssen wants to expand its high stakes case against Juno Pharmaceuticals over its HIV drug Prezista, alleging Juno’s plans to launch a generic version of the drug threaten another one of its patents.